中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 41 Issue 7
Jul.  2025
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2025  >  41(7): 1319-1326

Influence factors for the development and regression of metabolic dysfunction-associated fatty liver disease： A study based on the health check-up population in Beijing， China

DOI: 10.12449/JCH250715
  • 1.

    Fatty Liver Disease Treatment Center，Beijing YouAn Hospital，Capital Medical University，Beijing 100069，China

  • 2.

    Beijing Physical Examination Center，Beijing 100036，China

Research funding:

Beijing Municipal Administration of Hospitals Incubating Program (PX2023061);

Scientific Research Project of Beijing YouAn Hospital (YNKTXF2021003)

More Information
  • Corresponding author: ZHANG Jing， zjyouan@ccmu.edu.cn （ORCID： 0000-0002-3082-8330）
  • Received Date: 2024-11-15
  • Accepted Date: 2024-12-04
  • Published Date: 2025-07-25
    Abstract
  •   Objective  To investigate the clinical and metabolic factors associated with the development and regression of metabolic dysfunction-associated fatty liver disease （MAFLD） in the physical examination population.  Methods  A retrospective observational study was conducted on 6 809 individuals who underwent physical examination in a physical examination institution in Beijing from December 2013 to December 2019， with a mean follow-up time of 52.1±13.5 months. According to the new diagnostic criteria for MAFLD， these individuals were divided into MAFLD group and non-MAFLD group， and the two groups were compared in terms of demographic indicators， body measurement indicators， and laboratory indicators at the first （baseline） and last physical examinations. The two-independent-samples t test was used for comparison of normally distributed continuous data between two groups， and the Mann-Whitney U test was used for comparison of non-normally distributed continuous data between two groups； the chi-square test was used for comparison of categorical data. A Logistic regression analysis was used to investigate the impact of various observation indicators on the development and regression of MAFLD.  Results  In this study， there were 4 533 individuals （66.6%） in the non-MAFLD group at baseline， among whom 15.6% developed MAFLD at the last physical examination. Compared with the non-MAFLD population， the MAFLD population had significantly higher age （Z=-6.739）， number of male patients （χ2=178.534）， body weight （Z=-22.302）， body mass index （BMI） （Z=-22.818）， waist circumference （Z=-23.117）， hip circumference （Z=-18.446）， systolic blood pressure （SBP） （Z=-13.301）， diastolic blood pressure （DBP） （Z=-13.491）， fasting blood glucose （FBG） （Z=-11.787）， triglyceride （TG） （Z=-16.623）， low-density lipoprotein cholesterol （LDL-C） （Z=-10.256）， alanine aminotransferase （ALT） （Z=-14.250）， aspartate aminotransferase （AST） （Z=-7.481）， and proportion of patients with metabolic syndrome （MetS） at baseline （χ2=185.283）， and there were more patients with increases in body weight， waist circumference， hip circumference， TG， TC， ALT， and AST at the final physical examination （all P<0.05）； these patients had a lower level of HDL-C at baseline （Z=15.416）， and there were more patients with a reduction at the last physical examination （P<0.05）. There were 2 276 individuals （33.4%） in the MAFLD group at baseline， among whom 23.8% showed regression of MAFLD at the last physical examination. Compared with the population without regression of MAFLD， the population with regression of MAFLD had a significantly younger age （Z=2.185）， a significantly higher number of female patients （χ2=0.340）， significantly lower levels of body weight （Z=-8.909）， BMI （Z=-10.205）， waist circumference （Z=-11.183）， hip circumference （Z=-7.178）， SBP （Z=-3.627）， DBP （Z=-3.443）， TG （Z=-5.945）， ALT （Z=-9.664）， and AST （Z=-5.904）， and a significantly lower proportion of patients with MetS （χ2=42.082）， and there were more patients with reductions in body weight， waist circumference， hip circumference， blood pressure， TG， TC， ALT， and AST at the final physical examination （all P<0.05）； these patients had a higher level of HDL-C at baseline （Z=6.778）， and there were more patients with an increase at the last physical examination （P<0.05）. The multivariate Logistic regression analysis showed that sex and changes in body weight and HDL-C during physical examination were independently associated with the development and regression of MAFLD （all P<0.05）.  Conclusion  There is a relatively high prevalence rate of MAFLD among the physical examination population in Beijing， with a higher proportion of male patients. There are significant metabolic disorders and liver function abnormalities， and changes in body weight and HDL-C are the most important predictive indicators for the development and regression of MAFLD.

     

    • FullText(HTML)
  • loading
    • References(16)
  • [1]
    ZHOU JH, ZHOU F, WANG WX, et al. Epidemiological features of NAFLD from 1999 to 2018 in China[J]. Hepatology, 2020, 71( 5): 1851- 1864. DOI: 10.1002/hep.31150.
    [2]
    DUELL PB, WELTY FK, MILLER M, et al. Nonalcoholic fatty liver disease and cardiovascular risk: A scientific statement from the American heart association[J]. Arterioscler Thromb Vasc Biol, 2022, 42( 6): e168- e185. DOI: 10.1161/ATV.0000000000000153.
    [3]
    SUN DQ, TARGHER G, BYRNE CD, et al. An international Delphi consensus statement on metabolic dysfunction-associated fatty liver disease and risk of chronic kidney disease[J]. Hepatobiliary Surg Nutr, 2023, 12( 3): 386- 403. DOI: 10.21037/hbsn-22-421.
    [4]
    THOMAS JA, KENDALL BJ, DALAIS C, et al. Hepatocellular and extrahepatic cancers in non-alcoholic fatty liver disease: A systematic review and meta-analysis[J]. Eur J Cancer, 2022, 173: 250- 262. DOI: 10.1016/j.ejca.2022.06.051.
    [5]
    ESLAM M, SANYAL AJ, GEORGE J, et al. MAFLD: A consensus-driven proposed nomenclature for metabolic associated fatty liver disease[J]. Gastroenterology, 2020, 158( 7): 1999- 2014. e 1. DOI: 10.1053/j.gastro.2019.11.312.
    [6]
    Chinese Society of Hepatology, Chinese Medical Association. Guidelines for the prevention and treatment of metabolic dysfunction-associated(non-alcoholic) fatty liver disease(Version 2024)[J]. J Pract Hepatol, 2024, 27( 4): 494- 510. DOI: 10.3760/cma.j.cn501113-20240327-00163.

    中华医学会肝病学分会. 代谢相关(非酒精性)脂肪性肝病防治指南(2024年版)[J]. 实用肝脏病杂志, 2024, 27( 4): 494- 510. DOI: 10.3760/cma.j.cn501113-20240327-00163.
    [7]
    POWELL EE, WONG VW, RINELLA M. Non-alcoholic fatty liver disease[J]. Lancet, 2021, 397( 10290): 2212- 2224. DOI: 10.1016/S0140-6736(20)32511-3.
    [8]
    LEE H, LEE YH, KIM SU, et al. Metabolic dysfunction-associated fatty liver disease and incident cardiovascular disease risk: A nationwide cohort study[J]. Clin Gastroenterol Hepatol, 2021, 19( 10): 2138- 2147. e 10. DOI: 10.1016/j.cgh.2020.12.022.
    [9]
    YE Q, ZOU BY, YEO YH, et al. Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: A systematic review and meta-analysis[J]. Lancet Gastroenterol Hepatol, 2020, 5( 8): 739- 752. DOI: 10.1016/S2468-1253(20)30077-7.
    [10]
    HE YJ, YAO NF, TIAN F, et al. Prevalence and risk factors of MAFLD and its metabolic comorbidities in community-based adults in China: A cross-sectional study[J]. Diabetes Metab Syndr, 2024, 18( 3): 102973. DOI: 10.1016/j.dsx.2024.102973.
    [11]
    CEN C, FAN ZW, DING XJ, et al. Associations between metabolic dysfunction-associated fatty liver disease, chronic kidney disease, and abdominal obesity: A national retrospective cohort study[J]. Sci Rep, 2024, 14( 1): 12645. DOI: 10.1038/s41598-024-63386-0.
    [12]
    LV D, WANG ZP, MENG CQ, et al. A study of the relationship between serum asprosin levels and MAFLD in a population undergoing physical examination[J]. Sci Rep, 2024, 14( 1): 11170. DOI: 10.1038/s41598-024-62124-w.
    [13]
    BALAKRISHNAN M, LIU K, SCHMITT S, et al. Behavioral weight-loss interventions for patients with NAFLD: A systematic scoping review[J]. Hepatol Commun, 2023, 7( 8): e0224. DOI: 10.1097/HC9.0000000000000224.
    [14]
    JI TT, LI XF, YU YY, et al. Progress of lifestyle interventions for metabolic dysfunction-associated fatty liver disease[J]. J Clin Hepatol, 2023, 39( 8): 1789- 1796. DOI: 10.3969/j.issn.1001-5256.2023.08.004.

    纪童童, 李鑫飞, 于岩岩, 等. 代谢相关脂肪性肝病生活方式干预治疗进展[J]. 临床肝胆病杂志, 2023, 39( 8): 1789- 1796. DOI: 10.3969/j.issn.1001-5256.2023.08.004.
    [15]
    KIM NH, KIM JH, KIM YJ, et al. Clinical and metabolic factors associated with development and regression of nonalcoholic fatty liver disease in nonobese subjects[J]. Liver Int, 2014, 34( 4): 604- 611. DOI: 10.1111/liv.12454.
    [16]
    LIU FY, BI MS, JING X, et al. Multiparametric US for identifying metabolic dysfunction-associated steatohepatitis: A prospective multicenter study[J]. Radiology, 2024, 310( 3): e232416. DOI: 10.1148/radiol.232416.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Tables(7)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (424) PDF downloads(49) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return